People news: JAMA, King Pharmaceuticals

Share this article:

Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. But she was also criticized for letting some author conflicts go undisclosed. Formerly a vice dean at the Johns Hopkins University School of Medicine, DeAngelis plans to return to the school to develop a Center for Professionalism in Medicine and the Related Professions. A search is on for her replacement, and a successor will be named by next July, the journal said. According to Kantar Media's Journal Ad Review, JAMA ranked second among medical/surgical publications by 2009 ad revenue, while ad pages fell 12.8% vs. 2008.

King Pharmaceuticals named Jeffrey Bailey chief commercial officer. Bailey joins the company from Novartis, where he was a general manager. He will be responsible for all commercial activities in branded pharma and will lead sales, marketing, managed care, sales operations and business analytics.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions